Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 79 of 245 for:    "ottawa heart institute"

Prognostic Value of Stress SPECT Myocardial Perfusion Imaging With Half Dose 99mTc-Tetrofosmin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02019212
Recruitment Status : Completed
First Posted : December 24, 2013
Last Update Posted : April 13, 2017
Sponsor:
Information provided by (Responsible Party):
Renee Hessian, Ottawa Heart Institute Research Corporation

Brief Summary:
The purpose of this study is to evaluate the quality and prognostic ability of low dose 99mTc-tetrofosmin Myocardial Perfusion SPECT Imaging.

Condition or disease
Cardiovascular Disease

Detailed Description:

The objective of this study is to determine if myocardial perfusion imaging (MPI) using a new SPECT reconstruction software and a low dose (LD) of 99mTC-tetrofosmin will provide equal quality and prognostic value as a full dose (FD) of 99mTc-tetrofosmin myocardial perfusion SPECT imaging methodology.

The images of clinical patients from the Diagnostic Imaging Department will be assessed and compared for image quality and myocardial perfusion. The outcomes of participants that have had FD studies will be compared to those who have had LD studies. Consented participants will be contacted and will be asked to provide information on their cardiovascular health since the date of their LD or FD scan, such as non fatal myocardial infarction, death, congestive heart failure, admission to hospital with chest pain, further cardiac diagnostic testing, including angiography and early and late revascularization. The event information will be tabulated at 6, 12, 18, and 24 months for the LD and FD studies.

The study hypothesizes that there will be no difference in the quality and prognostic value between the LD and FD 99mTc-tetrofosmin SPECT MPI imaging protocols. The study hypothesizes that there will be no increase in repeat diagnostic testing and angiography with using the LD imaging protocol.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 4000 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Prognostic Value of Stress SPECT Myocardial Perfusion Imaging With Half Dose 99mTc-tetrofosmin
Study Start Date : June 2013
Actual Primary Completion Date : October 27, 2016
Actual Study Completion Date : October 27, 2016

Resource links provided by the National Library of Medicine


Group/Cohort
MPI Perfusion Imaging
Clinical patients who have undergone myocardial perfusion imaging with 99mTc



Primary Outcome Measures :
  1. Cardiovascular Outcomes [ Time Frame: 15 minutes ]
    The primary objective is to compare the cardiovascular outcomes of participants that have had FD studies to those that have had LD studies. These cardiovascular outcomes include myocardial infarction, death, congestive heart failure, hospitalization with chest pain, further diagnostic testing, including angioplasty, and early and late revascularization.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Clinical patients who have undergone myocardial perfusion imaging.
Criteria

Inclusion Criteria:

  • Participants who have completed the FD and LD MPI studies on the GE Infinia Haweye or GE NM 530 (CZT crystal) cameras
  • Retrospective participants must consent to the study interview(s) for data collection
  • Prospective participants must consent to follow up for data collection

Exclusion Criteria:

  • Unwilling to consent to data collection either retrospectively or in follow up prospectively

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02019212


Locations
Layout table for location information
Canada, Ontario
University of Ottawa Heart Insitute
Ottawa, Ontario, Canada, K1Y 4W7
Sponsors and Collaborators
Ottawa Heart Institute Research Corporation
Investigators
Layout table for investigator information
Principal Investigator: Renée Hessian, MD Ottawa Heart Institute Research Corporation

Layout table for additonal information
Responsible Party: Renee Hessian, MD, Ottawa Heart Institute Research Corporation
ClinicalTrials.gov Identifier: NCT02019212     History of Changes
Other Study ID Numbers: 20130446-01H
First Posted: December 24, 2013    Key Record Dates
Last Update Posted: April 13, 2017
Last Verified: April 2017

Keywords provided by Renee Hessian, Ottawa Heart Institute Research Corporation:
99mTc-tetrofosmin
myocardial perfusion imaging
SPECT
radiation

Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Technetium tc-99m tetrofosmin
Radiopharmaceuticals
Molecular Mechanisms of Pharmacological Action